When did Danaher Corp file this 8-K?

Danaher Corp (DHR) filed this Current Report (Form 8-K) with the SEC on May 7, 2026. The accession number assigned by EDGAR is 0000313616-26-000127.

What does an 8-K disclose?

Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).

What Item codes does an 8-K cover?

An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.

Where can I find Danaher Corp's prior current reports on EDGAR?

The SEC EDGAR browser lists every 8-K Danaher Corp has filed under CIK 313616, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.

Boardroom Alpha

DHR · Current Report (Form 8-K) · Filed May 7, 2026

Danaher Corp — Current Report (Form 8-K)

Form

8-K

Filed

May 7, 2026

Period

May 5, 2026

Ticker

DHR

Accession

0000313616-26-000127

Danaher Corp on Boardroom Alpha View on SEC EDGAR

Boardroom Alpha · Filing insights

Danaher shareholders approved the Amended and Restated Omnibus Incentive Plan, increasing the share reserve by 20 million shares and extending its term to 2036. They also elected directors and approved the independent auditor and the executive compensation advisory vote.

About Danaher Corp

Market cap

$151.9B

1Y TSR

+1.7%

3Y TSR

−2.5%

Board grade

Sector

Healthcare

CEO

Montgomery Julie A Sawyer

Last annual meeting: May 5, 2026 · View full Danaher Corp profile →

dhr-20260505

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________

FORM 8-K

__________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 5, 2026

__________________


DANAHER CORPORATION
			(Exact Name of Registrant as Specified in Its Charter)

__________________


Delaware		001-08089	59-1995548
(State or Other Jurisdiction of Incorporation)		(Commission File Number)	(IRS Employer Identification No.)

2200 Pennsylvania Avenue, N.W.,			20037-1701
Suite 800W
Washington,	DC
(Address of Principal Executive Offices)			(Zip Code)

202-828-0850

(Registrant’s Telephone Number, Including Area Code)


Not applicable
(Former Name or Former Address, if Changed Since Last Report)

__________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.01 par value	DHR	New York Stock Exchange

0.200% Senior Notes due 2026	DHR/26	New York Stock Exchange
2.100% Senior Notes due 2026	DHR 26	New York Stock Exchange
1.200% Senior Notes due 2027	DHR/27	New York Stock Exchange
0.450% Senior Notes due 2028	DHR/28	New York Stock Exchange
Floating Rate Senior Notes due 2028	DHR 28	New York Stock Exchange
2.500% Senior Notes due 2030	DHR 30	New York Stock Exchange
3.250% Senior Notes due 2030	DHR 30A	New York Stock Exchange
0.750% Senior Notes due 2031	DHR/31	New York Stock Exchange
3.625% Senior Notes due 2034	DHR 34	New York Stock Exchange
4.000% Senior Notes due 2038	DHR 38	New York Stock Exchange
1.350% Senior Notes due 2039	DHR/39	New York Stock Exchange
1.800% Senior Notes due 2049	DHR/49	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging growth company						☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


ITEM 5.02			DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

On May 5, 2026, at the annual meeting of shareholders (the “Annual Meeting”) of Danaher Corporation (the “Company”), as further described in Item 5.07 below, the Company’s shareholders approved the Amended and Restated Danaher Corporation Omnibus Incentive Plan (the “Plan”). Previously, the Board of Directors of the Company approved the Plan (subject to shareholder approval) to increase the Plan’s share reserve by 20 million shares of Common Stock and extend the Plan term to May 5, 2036.

A description of the material terms of the Plan was set forth in the Company’s proxy statement for the Annual Meeting which was filed with the U.S. Securities and Exchange Commission on March 25, 2026. The description of the Plan contained herein is qualified in its entirety by reference to the Plan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.


ITEM 5.07			SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The Company’s annual meeting of shareholders was held on May 5, 2026. At the annual meeting, the Company’s shareholders voted on the following proposals:

1. To elect the eleven directors named in the Company’s proxy statement to terms expiring in 2027. Each nominee for director was elected by a vote of the shareholders as follows:


	For	Against	Abstain	Broker Non-Votes
Rainer M. Blair	588,328,554	7,060,627	394,475	36,129,645
Feroz Dewan	572,679,518	21,482,953	1,621,185	36,129,645
Linda Filler	484,585,744	110,431,359	766,553	36,129,645
Charles W. Lamanna	590,861,836	4,510,517	411,303	36,129,645
Teri List	462,346,887	132,804,946	631,823	36,129,645
Mitchell P. Rales	584,749,121	10,636,383	398,152	36,129,645
Steven M. Rales	578,334,314	16,812,806	636,536	36,129,645
A. Shane Sanders	439,300,748	155,803,065	679,843	36,129,645
Alan G. Spoon	550,524,407	44,853,170	406,079	36,129,645
Raymond C. Stevens, PhD	474,476,236	120,672,805	634,615	36,129,645
Elias A. Zerhouni, MD	538,619,559	55,838,928	1,325,169	36,129,645

2. To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The proposal was approved by a vote of shareholders as follows:


For			595,609,858
Against			35,828,479
Abstain			474,964

3. To approve on an advisory basis the Company’s named executive officer compensation. The proposal was approved by a vote of shareholders as follows:


For			553,754,519
Against			41,555,863
Abstain			473,274
Broker Non-Votes			36,129,645

4. To approve the Plan. The proposal was approved by a vote of shareholders as follows:


For			553,836,647
Against			41,437,418
Abstain			509,591
Broker Non-Votes			36,129,645


ITEM 9.01	FINANCIAL STATEMENTS AND EXHIBITS

(c)	Exhibits:

Exhibit No.		Description
10.1		Amended and Restated Danaher Corporation Omnibus Incentive Plan (Incorporated by reference from Appendix B to Danaher Corporation’s Proxy Statement on Schedule 14A filed on March 25, 2026)

104		The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			DANAHER CORPORATION

Date:	May 7, 2026	By:	/s/ James F. O'Reilly
			James F. O'Reilly
			Senior Vice President, Deputy General Counsel and Secretary; Chief Sustainability Officer

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

See Filings Intelligence Schedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Danaher Corp (DHR)

8-KCurrent Report
Aug 3, 2026
8-KCurrent Report
Jul 21, 2026
10-QQuarterly Report
Jul 21, 2026
8-KCurrent Report
Jun 3, 2026
8-KCurrent Report
Apr 29, 2026
8-KCurrent Report
Apr 21, 2026
10-QQuarterly Report
Apr 21, 2026
8-KCurrent Report
Apr 17, 2026
DEFA14AAdditional Proxy Materials
Mar 25, 2026
DEF 14AProxy Statement
Mar 25, 2026
10-KAnnual Report
Feb 24, 2026
8-KCurrent Report
Feb 17, 2026

Continue researching

Reference

Frequently asked questions

When did Danaher Corp file this 8-K?: Danaher Corp (DHR) filed this Current Report (Form 8-K) with the SEC on May 7, 2026. The accession number assigned by EDGAR is 0000313616-26-000127.
What does an 8-K disclose?: Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?: Danaher shareholders approved the Amended and Restated Omnibus Incentive Plan, increasing the share reserve by 20 million shares and extending its term to 2036. They also elected directors and approved the independent auditor and the executive compensation advisory vote. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?: An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Danaher Corp's prior current reports on EDGAR?: The SEC EDGAR browser lists every 8-K Danaher Corp has filed under CIK 313616, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer